Key Drivers
- Margin Recovery
- Liquidity Strength
- Cash Conversion
AIAI Summary
BLFS has shifted from a survival story to a credibility test, with strong revenue growth and restored profitability suggesting the core franchise is working, but negative free cash flow and a stretched valuation mean the stock likely needs several more quarters of real cash-generating execution before the market re-rates it.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Recovery
- •Liquidity Strength
- •Cash Conversion
BLFS posted a sharp Q1 profitability rebound with strong liquidity and low leverage, but weak cash conversion, thin operating margins, and a rich valuation temper the outlook.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Weak bounce
- •Support test
BLFS has turned mildly bearish as the rebound faded into lower highs, with price slipping back toward $20.7–$21.0 support and facing resistance near $21.7–$22.0.
Rally from the $19.99 low faded quickly after the $23.12 peak, signaling weakening momentum
Sentiment & News
Key News Insights:
- •Earnings beat
- •Revenue growth
- •Product award
BioLife Solutions delivered a strong Q1 beat with 25% revenue growth, solid margins and EBITDA, while product innovation recognition supports the long-term story despite recent share-price weakness.
The results and award are constructive for fundamentals, but the stock may need technical recovery before sentiment fully improves
Similar Companies in Healthcare
Other companies in the same sector with AI ratings